About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
SLE, Systemic sclerosis, vasculitis, dermatomyositis, Sjogren Syndrome, antiphospholipid síndrome and autoinflammatory síndromes.
1.-Epigenetic and Genetic studies in Autoimmune systemic diseases
2.-Development of new diagnostic criteria for the autoimmune systemic diseases.
3.-Identification of new diagnostic diseases biomarkers and for assessing disease activity.
4- Evaluation of new immunosuppressive drugs, biological therapies and antifibrotic agents in these conditons.
5.-Epidemiologic and Morbi-mortality studies
IP: -
We are currently enrolled in this multicentre study supported by the “EULAR Sjögren’s Task Force” to elaborate and agree on a systemic disease activity index for patients with primary Sjögren’s syndrome, that will be useful in the management of the disease. This study is coordinated by Dr. Raphaele Seror from the “Service de Rheumatologie Hôpital Bicêtre”, France.
IP: Roser Solans Laque
We are currently enrolled in this multicentre study to investigate the possible influence of the genetic background in the disease pathogenesis, and to try to establish links between genetic variations and different clinical and biological patterns. The research is led by Prof. Javier Martín from the "Instituto López-Neyra" of Parasitology, CSIC (Granada). We contribute by sending samples from our cohort of patients along with the clinical data, and reviewing the results. It is supported by a SAS grant.
We are currently enrolled in this multicentre study coordinated by Dr. Seema Kalra from University Hospital of North Staffordshire (UK). The study aims to define new diagnostic criteria for neuro-Behçet disease. A set of neurologists, rheumatologists and specialists in Internal Medicine from different countries, experts in the diagnosis and management of this disease, will try to define a new set of diagnostic criteria based on clinical expertise, and in the most new laboratory and radiology modern tests.
IP: Francesc Miro Mur Collaborators: Jaume Alijotas Reig, José Pardos Gea, Ariadna Anunciacion Llunell Funding agency: Instituto de Salud Carlos III Funding: 102500 Reference: PI24/01302 Duration: 01/01/2025 - 31/12/2027
IP: Adria Curran Fàbregas Collaborators: Anna Sala Cunill, Vicenç Falcó Ferrer, Yolima Cossio Gil, Ignasi Cardona Pascual, Paula Suanzes Diez, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, Maria Belén Gutiérrez Iglesias, Silvina Andrea Magnani Funding agency: Laboratorio ViiV Healthcare Funding: 55000 Reference: VIIV/BECAS/2023/CURRAN Duration: 15/01/2024 - 14/01/2026
IP: Dimelza Osorio Sánchez Collaborators: Jesús Martínez Pérez, Karla Salas Gama, Percy Efrain Pantoja Bustillos, Anna Sala Cunill, Roser Martin Campos, Julia Salvador Lodosa, Daniel López Torres, Victoria Valls Comamala, Marta Aguayo Álvarez , Susana Malgrat Caballero, Cristopher Alan Mazo Torre Funding agency: Instituto de Salud Carlos III Funding: 62920 Reference: PI22/00371 Duration: 01/01/2023 - 30/06/2027
IP: Ernesto Trallero Araguas Collaborators: Albert Selva O'Callaghan, Raul Tortosa Mendez, Albert Gil Vila, Gloria Aparicio Español, Hugo Fernando Avalos Bogado Funding agency: Instituto de Salud Carlos III Funding: 135520 Reference: PI22/00708 Duration: 01/01/2023 - 31/12/2026
PhD student: Andreu Fernández Codina, Andreu Fernández Codina, Andreu Fernández Codina, Andreu Fernández Codina Director/s: Inés de Torres Ramirez, Fernando Martínez Valle, Roser Solans Laque University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Director/s: Javier Cortés Castan, Eva Muñoz Couselo, Vicente Peg Camara University: Universitat Autònoma de Barcelona Year: 2019
PhD student: Jaume Mestre Torres Director/s: Roser Solans Laque University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Sara Nieves Maurel Ibáñez Director/s: José Alegre Martin University: Universidad Autònoma de Barcelona Year: 2018
A Vall d’Hebron team demonstrates, for the first time, the potential of optical genome mapping to detect genetic alterations associated with this rare disease that are not identified using conventional methods.
The study describes the first documented case worldwide of hereditary angioedema transmission through assisted reproduction.
15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.
